详情页 - 聚合机构库演示平台

资源类型：

文章类型：

作者：

Qian, Jiang[1] * ; Shi, Dayu[1] ; Li, Zongru[1] ; Hou, Yue[1] ; Hu, Yu[2] ; Li, Weiming[3] ; Liu, Xiaoli[4] ; Xu, Na[4] ; Song, Yongping[5] ; Zhang, Gongli[5] ; Meng, Li[6] ; Hong, Zhenya[6]

; Liu, Bingcheng[7,8] ; Li, Yan[9,10] ; Chen, Suning[11] ; Xue, Mengxing[12] ; Zhu, Huanling[13] ; Li, He[13] ; Du, Xin[14] ; Lou, Jin[14] ; Zhang, Xiaohan[14] ; Liang, Yang[15] ; Dai, Yujun[16] ; Chen, Zi[17] ; Niu, Qian[17] ; Men, Lichuang[17] ; Yang, Dajun[18,19] ; Zhai, Yifan[17,20] ; Huang, Xiaojun[21] ;

单位： [1]Peking Univ, Peking Univ Peoples Hosp, Inst Hematol, Beijing, Peoples R China [2]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Peoples R China [3]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China [4]Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China [5]Zhengzhou Univ, Affiliated Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China [6]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China [7]Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Tianjin, Peoples R China [8]Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China [9]Natl Clin Res Ctr Blood Dis, Inst Hematol, Tianjin, Peoples R China [10]Natl Clin Res Ctr Blood Dis, Blood Dis Hosp, Tianjin, Peoples R China [11]Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China [12]Soochow Univ, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China [13]Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China [14]Shenzhen Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp 2, Div Hematol, Shenzhen, Peoples R China [15]Sun Yat Sen Univ, Ctr Canc, Dept Hematol Oncol, Guangzhou, Peoples R China [16]Sun Yat Sen Univ, Ctr Canc, Dept Hematol Oncol, Shanghai, Peoples R China [17]Guangzhou Healthquest Pharma Co Ltd, Guangzhou, Peoples R China [18]Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China [19]Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China [20]Ascentage Pharma Grp Inc, Rockville, MD USA [21]Chinese Acad Med Sci, Key Tech Diag & Treatments Hematol Malignancies, Res Unit, 2019RU029, Beijing, Peoples R China

出处：

DOI：

ISSN：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 1 区

医学

小类 | 1 区血液学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区血液学

JCR分区：

出版当年[2019]版：

Q1 HEMATOLOGY

最新[2023]版：

Q1 HEMATOLOGY

第一作者：

第一作者单位： [1]Peking Univ, Peking Univ Peoples Hosp, Inst Hematol, Beijing, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 (T315I)-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

文献详情